Investing.com - Erytech Pharma ADR reported on Monday fourth quarter earnings that matched analysts' forecasts and revenue that was inline with expectations.
Erytech Pharma ADR announced earnings per share of $-1.08 on revenue of $2.33M. Analysts polled by Investing.com anticipated EPS of $-1.08 on revenue of $2.33M.
Erytech Pharma ADR shares are down 14% from the beginning of the year, still down 42.37% from its 52 week high of $13.95 set on August 11, 2020. They are under-performing the S&P Merval which is down 9.63% from the start of the year.
Erytech Pharma ADR follows other major sector earnings this month
Erytech Pharma ADR's report follows an earnings beat by SoftBank Group on February 8, who reported EPS of $2.97 on revenue of $14.41B, compared to forecasts EPS of $0.0374 on revenue of $12.93B.
HSBC Holdings PLC ADR had beat expectations on February 23 with fourth quarter EPS of $0.09 on revenue of $11.82B, compared to forecast for EPS of $0.042 on revenue of $11.38B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar